{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:30Z","timestamp":1790938110133,"version":"4.1.0"},"reference-count":27,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>Introduction: Primary central nervous system lymphoma (PCNSL) is a rare subtype of aggressive extranodal non-Hodgkin lymphoma. Currently, there is no standard of care for the treatment of refractory or relapsed PCNSL (r\/r PCNSL). We conducted a prospective single-arm phase II study to evaluate zanubrutinib plus cytarabine for r\/r PCNSL. Methods: Using Simon\u2019s two-stage design, we analyzed 34 patients who received high-dose cytarabine (3.0 g\/m2 once daily) for 2 days and zanubrutinib (160 mg twice daily) for 21 days each cycle for up to 6 cycles. The study was registered at &lt;ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"&gt;www.chictr.org.cn&lt;\/ext-link&gt; as #ChiCTR2000039229. Results: The median follow-up was 19 months. The overall response rate was 64.7% (95% confidence interval [CI], 47.9\u201378.5%) with a complete remission or unconfirmed complete remission rate of 47.1% (16\/34) and a partial remission rate of 17.6% (6\/34). The median progression-free survival was 4.5 months (95% CI, 1.5\u20139.4), and the median OS was 18 months (95% CI, 9.5 to not estimable). The median duration of the response was 9 months (95% CI, 3.2 to not estimable). The most common treatment-emergent adverse events were thrombocytopenia (55.9%). No treatment-related death occurred. Conclusion: Zanubrutinib and cytarabine showed efficacy in r\/r PCNSL with an acceptable safety profile. <\/jats:p>","DOI":"10.1159\/000537995","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:23:07Z","timestamp":1709274187000},"page":"555-563","source":"Crossref","is-referenced-by-count":11,"title":["Zanubrutinib plus Cytarabine in Patients with Refractory\/Relapsed Primary Central Nervous System Lymphoma"],"prefix":"10.1159","volume":"147","author":[{"given":"Zhiguang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01356-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou223"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10121076"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01582-5"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1462700"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1677157"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1074"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.018"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1994-8"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0489"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004779"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001158"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835496"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.024"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760405"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S309408"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010361"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now033"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092100"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16451"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012515"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901797"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/147\/5\/555\/4282101\/000537995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/aha\/article-pdf\/147\/5\/555\/4282101\/000537995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:08:43Z","timestamp":1745420923000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000537995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9,26]]},"published-print":{"date-parts":[[2024,9,30]]}},"URL":"https:\/\/doi.org\/10.1159\/000537995","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}